Evidence map›Paper›PMID 33868229›Full record

ArticleFrontiers in immunology2021

Pre-Existing Humoral Immunity Enhances Epicutaneously-Administered Allergen Capture by Skin DC and Their Migration to Local Lymph Nodes.

Pierre-Louis Hervé, Camille Plaquet, Noémie Assoun, Nathalie Oreal, Laetitia Gaulme, Audrey Perrin, Adeline Bouzereau, Véronique Dhelft, Jean-Louis Labernardière, Lucie Mondoulet and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Pierre-Louis HervéResearch and Innovation, DBV Technologies, Montrouge, France.
Camille PlaquetResearch and Innovation, DBV Technologies, Montrouge, France.
Noémie AssounResearch and Innovation, DBV Technologies, Montrouge, France.
Nathalie OrealResearch and Innovation, DBV Technologies, Montrouge, France.
Laetitia GaulmeResearch and Innovation, DBV Technologies, Montrouge, France.
Audrey PerrinResearch and Innovation, DBV Technologies, Montrouge, France.
Adeline BouzereauResearch and Innovation, DBV Technologies, Montrouge, France.
Véronique DhelftResearch and Innovation, DBV Technologies, Montrouge, France.
Jean-Louis LabernardièreResearch and Innovation, DBV Technologies, Montrouge, France.
Lucie MondouletResearch and Innovation, DBV Technologies, Montrouge, France.
Hugh A SampsonResearch and Innovation, DBV Technologies, New York, NY, United States.
DBV Technologies (France) · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Due to its richness in antigen presenting cells, e.g., dendritic cells (DC), the skin has been identified as a promising route for immunotherapy and vaccination. Several years ago, a skin delivery system was developed based on epicutaneous patches allowing the administration of antigen through intact skin. Using mouse models, we have shown that epicutaneous allergen application leads to a rapid uptake and transport of allergen-positive cells to skin-draining lymph nodes (LN). This occurred primarily in animals previously sensitized to the same allergen. In that context, we sought to better understand the role of the specific preexisting immunity in allergen capture by skin DC and their subsequent migration to LN. Specifically, we investigated the role of humoral immunity induced by sensitization and the involvement of IgG Fc receptors (FcγR). Epicutaneous patches containing fluorescently-labeled ovalbumin (OVA) were applied to naïve mice that had previously received either sera or purified IgG isolated from OVA-sensitized mice. To investigate the involvement of FcγR, animals received 2.4G2 (anti-FcγRII/RIII) blocking antibody, 24 hours before patch application. Mice that received sera or purified IgG originating from OVA-sensitized mice showed an increase in the quantity of OVA-positive DC in skin and LN. Moreover, the blockade of FcγR reduced the number of OVA-positive DC in LN to a level similar to that observed in naïve animals. Overall, these results demonstrate that preexisting specific-IgG antibodies are involved in allergen capture by skin DC following EPIT through the involvement of antigen-specific IgG-FcγR.

Indexed as

Immunity, HumoralAllergensAnimalsBiomarkersCell MovementDisease Models, AnimalHypersensitivityImmunizationImmunoglobulin EImmunoglobulin GImmunophenotypingLangerhans CellsLymph NodesMiceReceptors, FcAllergensBiomarkersImmunoglobulin EImmunoglobulin GReceptors, Fcallergen captureepicutaneous deliveryFc receptors (FcR)preexisting immunityskin dendritic cells

Identifiers

PMID33868229
PMCPMC8044905
OpenAlexW3146198842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.